Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + eribulin
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cyclophosphamide + eribulin is an investigational combination chemotherapy regimen studied primarily for the treatment of advanced or metastatic breast cancer. Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell death, while eribulin is a microtubule dynamics inhibitor that binds to the plus ends of microtubules, preventing their elongation and causing irreversible mitotic arrest. Eribulin also has additional effects on the tumor microenvironment, including reversal of epithelial-to-mesenchymal transition (EMT) and remodeling tumor vasculature to improve perfusion. The combination has shown encouraging clinical benefit rates in heavily pretreated patients with advanced breast cancer in phase Ib/II studies, though it remains experimental and not FDA-approved as a fixed combination[1][2][3][5].
- Brand names
- Halaven + Cytoxan
- Other names
- EC (in clinical trial context)eribulin mesylate + cyclophosphamide
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))Microtubule
Beyond the preview
Go deeper on cyclophosphamide + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + eribulin.